Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial.

Nauck, Michael A; Del Prato, Stefano; Meier, Juris J; Durán-García, Santiago; Rohwedder, Katja; Elze, Martina; Parikh, Shamik J
Diabetes care; 2011 Sep;34(9):2015-22. PMID: 21816980
Diabetes Centre, Bad Lauterberg, Germany.


Although initially effective, sulfonylureas are associated with poor glycemic durability, weight gain, and hypoglycemia. Dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), reduces hyperglycemia by increasing urinary glucose excretion independent of insulin and may cause fewer of these adverse effects. We compared the efficacy, safety, and tolerability of dapagliflozin with the sulfonylurea glipizide in patients with type 2 diabetes inadequately controlled with metformin monotherapy.